Dr. Martin Nicklasson, Swedish citizen, has served as a member of the Board of Directors since 2013. He served as Chairman of the Board from April 2013-April 2016. Dr. Nicklasson is an honorary Associate Professor at the Pharmaceutical Faculty, University of Uppsala (Sweden) since 1985. From 2007 to 2010, Dr. Nicklasson served as president and chief executive officer of Biovitrum AB and Swedish Orphan Biovitrum AB. From 1999 to 2007 he held various executive vice president positions at AstraZeneca Plc., and acted as a member of the Executive Committee. Dr. Nicklasson is member of the board of Biocrine AB (Sweden) and chairman of the board of directors of Kymab Group Ltd. (UK), Orexo AB (Sweden) and Zealand Pharma A/S (Denmark). Dr. Nicklasson is a certified pharmacist and holds a Ph.D. in Pharmaceutical Technology from the University of Uppsala.